Table 1.
Patient characteristics of all patients and depending on sub-groups
| All patients (n = 54) |
FDG+/PSMA- (n = 18) |
No FDG+/PSMA- (n = 36) |
|
|---|---|---|---|
| Age (years) | 71.4 (52–90) | 70.4 (58–82) | 71.9 (52–90) |
| Time since diagnosis of prostate cancer (years) | 7.7 (1.7–26.3) | 6.3 (1.8–11.6) | 8.4 (1.7–26.3) |
| Gleason score | 8 (5–10)* | 8 (7–10)~ | 8 (5–10)# |
| PSA (ng/ml) | 450 (0.07–5000) | 543 (0.07–5000) | 404 (5–2650) |
| ECOG | 0–3 | 0–3 | 0–2 |
| Sites of disease: | n (patients) | n (patients) | n (patients) |
| Prostate/local | 16 | 4 | 12 |
| Lymph node | 33 | 12 | 21 |
| Bone | 52 | 18 | 34 |
| Liver | 13 | 9 | 4 |
| Lung | 8 | 4 | 4 |
| Other | 9 | 5 | 4 |
| Previous treatment: | n (patients) | n (patients) | n (patients) |
| Prostatectomy | 28 | 9 | 19 |
| Radiotherapy to prostate/ prostate bed | 31 | 13 | 18 |
| ADT | 54 | 18 | 36 |
| Abiraterone | 44 | 15 | 29 |
| Enzalutamide | 29 | 9 | 20 |
| Docetaxel | 37 | 13 | 24 |
| Cabazitaxel | 12 | 3 | 9 |
| [223Ra]Dichloride | 8 | 3 | 5 |
| Selective internal radiation therapy | 2 | 0 | 2 |
| PSMA RLT | 2 | 1 | 1 |
| Prostvac | 1 | 1 | 0 |
| Estramustin | 1 | 0 | 1 |
| Median lines of treatment before RLT | 3.5 (2–6) | 3.5 (2–6) | 3.5 (2–6) |
| Number of RLT cycles | n (patients) | n (patients) | n (patients) |
| 1 cycle | 54 | 18 | 36 |
| 2 cycles | 44 | 12 | 32 |
| 3 cycles | 26 | 5 | 21 |
| 4 cycles | 15 | 1 | 14 |
PSA prostate specific antigen, ECOG performance status according to Eastern Cooperative Oncology Group, ADT androgen deprivation therapy, PSMA RLT prostate-specific membrane antigen-targeted radioligand therapy, other sites of disease: kidney, adrenal gland, testis, tumor in the (retro-) peritoneum, pleura, leptomeningeal carcinomatosis; unknown in *n = 6, ~ n = 1, #n = 5